viewHarvest One Cannabis Inc.

Harvest One Cannabis posts record revenue, enjoying boost from Dream Water subsidiary

Highlights of its fiscal first quarter include agreements to supply adult-use cannabis to four provinces: British Columbia, Ontario, Manitoba and Saskatchewan

A greenhouse with marijuana plants
Cannabis company Harvest One says it maintained a strong balance sheet with a cash balance of C$48.3 million

Harvest One Cannabis Inc (CVE:HVT) (OTCMKTS:HRVOF) said it posted record quarterly revenue driven by its Dream Water subsidiary’s sales and bulk sales to other licensed producers.

For its fiscal first quarter ended September 30, the Vancouver-based company said Thursday that its revenue surged to C$1.68 million, almost 10 times the C$174,544 reported a year earlier. Another factor in the boost was an initial recreational-cannabis sale to the province of British Columbia.

READ: MMJ Group Holdings completes sale of unit to Harvest One Cannabis for C$8 million

Highlights included agreements to supply adult-use cannabis to four provinces: Ontario, Manitoba and Saskatchewan, as well as British Columbia.

“I am proud to say Harvest One has executed on our roll-out strategy, meeting all provincial obligations and establishing the basis for successful long-term relationships with both public and private retailers,” said Grant Froese, who assumed the role of CEO in July. “The work we are doing now lays the foundation for a landmark year in 2019, when cannabis companies will be judged on execution and financial performance.”

The company also acquired a 19.99% interest in a British Columbia-based luxury retail group known as Burb Cannabis Corp. Burb expects to open eight to 10 stores in BC in 2019. The investment falls within the allowable maximum investment of 20% established by the British Columbia government, according to Harvest One.

Harvest One added that it maintained a strong balance sheet with a cash balance of C$48.3 million. Its comprehensive loss widened to C$5.8 million, or C$0.03 per share, from C$1.9 million, or C$0.02 per share.

The company cited favorable results in Phase 2 clinical trials of its Satipharm capsules for the treatment of pediatric epilepsy. The median seizure reduction was 82% in the 12-week treatment period. These results were recently presented at the Epilepsy Society of Australia Conference.

Harvest One recently closed its acquisition of Phytotech Therapeutics, adding research capabilities to support product development for Satipharm.

Shares of Harvest One slipped C$0.01 to C$0.42 in Thursday's Canadian trading. They were down US$0.01 to US$0.31 on the OTC market.

Contact Dennis Fitzgerald at [email protected]

Quick facts: Harvest One Cannabis Inc.

Price: 0.09 CAD

Market: TSX-V
Market Cap: $19.36 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Harvest One Cannabis Inc. named herein, including the promotion by the Company of Harvest One Cannabis Inc. in any Content on the Site, the...



Full interview: Harvest One Cannabis receives Health Canada cultivation...

Harvest One Cannabis Inc (CVE:HVT) (OTCMKTS:HRVOF) Senior Vice President of Corporate & Public Affairs Will Stewart tells Proactive the cannabis company has earned a cannabis cultivation license from Health Canada for phase one of its Mission Road facility in Duncan, British...

on 15/10/19

2 min read